Subscribe To
ZNTL / Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from
ZNTL News
By Seeking Alpha
August 24, 2023
Zentalis: A Buy As Small Molecule Trials Continue To Advance
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's financials show more_horizontal
By 24/7 Wall Street
June 22, 2023
Matrix Capital Infuses $108 Million Into Zentalis Toward Promising Cancer Therapeutics
Shares of Zentalis Pharmaceuticals Inc (US:ZNTL) are cooling off a bit Thursday after yesterday's 4% rise capped a five-day rally of 17.8%. more_horizontal
By The Motley Fool
June 2, 2023
Why Shares of Zentalis Pharmaceuticals Dropped This Week
Zentalis is a clinical-stage biotech that is focusing on cancer therapies. The stock is up more than 29% this year. more_horizontal
By GlobeNewsWire
April 26, 2023
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for more_horizontal
By GlobeNewsWire
February 1, 2023
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company fo more_horizontal
By Zacks Investment Research
August 26, 2022
Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should Know
Zentalis Pharmaceuticals, Inc. (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks more_horizontal
By Benzinga
April 27, 2022
Pfizer Injects $25M Via Equity In Zentalis Pharma
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE: PFE) for $25 million. The o more_horizontal